Gwill York - Feb 1, 2024 Form 3 Insider Report for Alto Neuroscience, Inc. (ANRO)

Role
Director
Signature
/s/ Erin R. McQuade, Attorney-in-Fact
Stock symbol
ANRO
Transactions as of
Feb 1, 2024
Transactions value $
$0
Form type
3
Date filed
2/1/2024, 06:50 PM
Next filing
Feb 7, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ANRO Series A Preferred Stock Feb 1, 2024 Common Stock 23.9K Direct F1
holding ANRO Stock Option (Right to Buy) Feb 1, 2024 Common Stock 33.7K $2.32 Direct F2
holding ANRO Stock Option (Right to Buy) Feb 1, 2024 Common Stock 11.2K $6.23 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A Preferred Stock is convertible at any time, at the holder's election, and will automatically convert into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.2241 for 1 basis into the number of shares of Common Stock shown in column 3 and has no expiration date.
F2 One thirty-sixth (1/36th) of the shares underlying the option vested or shall vest on a monthly basis commencing on the one-month anniversary of August 10, 2021, subject to the Reporting Person's continuous service through such vesting date.
F3 100% of the shares underlying the option shall vest on October 12, 2024, subject to the Reporting Person's continuous service through such vesting date.